NASDAQ:FOLD Archives - BioPharmaJournal

Amicus Therapeutics, Inc. (NASDAQ: FOLD) Gets a Patent For Migalasat

Matt Wade - April 25, 2022 0

Amicus Therapeutics (NASDAQ: FOLD) Receives MAA Approval From EMA For AT-GAA...

Gavins Felicity - December 17, 2021 0

Amicus Therapeutics, Inc. (NASDAQ: FOLD) Announces that it is Preparing to...

Gavins Felicity - October 12, 2021 0

Amicus Therapeutics, Inc. (NASDAQ:FOLD) Reports Topline Results Of AT-GAA In Phase...

Ward Sport - February 22, 2021 0

Amicus Therapeutics (NASDAQ:FOLD) Commences Rolling BLA For AT-GAA In Treatment Of...

Gavins Felicity - December 11, 2020 0

Amicus Therapeutics Inc. (NASDAQ:FOLD) Reports Q3 2020 Financial Results With Galafold...

Kate Hudson - November 13, 2020 0

Amicus Therapeutics (NASDAQ:FOLD) Announce Encouraging Preliminary AT-GTX-501 Gene Therapy Results In...

Gavins Felicity - October 28, 2020 0

Amicus Therapeutics (NASDAQ:FOLD) Granted PRIME Designation By European Medicines Agency For...

Ward Sport - September 30, 2020 0

Amicus Therapeutics, Inc. (NASDAQ:FOLD) Posts Revenues Of $62.4 Million In Q2...

Gavins Felicity - August 26, 2020 0

Senti Biosciences Inc (NASDAQ:SNTI) surges post CEO’s participation on Gene Regulation...

Matt Wade - October 4, 2022 0

Stock of Senti Biosciences (NASDAQ:SNTI) last traded at $5.14 USD, a gain of +2.64 (105.60%). More than 68,212,695 shares exchanged hands compared to an...

Wellbeing Digital Sciences ($KONEF) To Participate in the Cantor Fitzgerald Symposium...

October 4, 2022

FingerMotion Inc (NASDAQ:FNGR) surge may be attributed to retail traders

September 30, 2022

Revance Therapeutics Inc (NASDAQ:RVNC) surges while rest of the Wall Street...

September 30, 2022

DoorDash Inc (NYSE:DASH) could slip further to the downside and here’s...

September 23, 2022

Tag: NASDAQ:FOLD

Recent Post